Skip Navigation

JNCI Monographs 1998 1998(23):89-93;
© 1998 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rooney, C. M.
Right arrow Articles by Heslop, H. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rooney, C. M.
Right arrow Articles by Heslop, H. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute Monographs, No. 23, 89-93, 1998
© 1998 Oxford University Press

Immunotherapy for Epstein-Barr Virus-Associated Cancers

Cliona M. Rooney, Marie A. Roskrow, Colton A. Smith, Malcolm K. Brenner, Helen E. Heslop*

* Affiliations of authors: C. M. Rooney, M. A. Roskrow, C. A. Smith (Department of Virology and Molecular Biology), M. K. Brenner, H. E. Heslop (Department of Hematology and Oncology), St. Jude Children's Research Hospital, Memphis, TN.

Correspondence to: Cliona M. Rooney, Ph.D., Department of Pediatrics-Hematology/Oncology, Texas Children's Hospital, Baylor College of Medicine, 6621 Fannin St., Houston, TX 77030-2399. E-mail: cmrooney{at}msmail.his.tch.tmc.edu

Epstein-Barr virus (EBV)-associated lymphoproliferative disease (EBV-LPD) is a frequently fatal complication of organ transplantation and human immunodeficiency virus (HIV) infection. We have studied the safety and efficacy of adoptively transferred, gene-marked virus-specific cytotoxic T lymphocytes (CTLs) as prophylaxis and treatment of EBV-LPD in recipients of T-cell-depleted allogeneic bone marrow. In 42 patients treated prophylactically, no toxicity was experienced. None of these patients developed EBV-LPD, in contrast with eight of 53 (15%) patients who did not receive prophylactic CTL. Three patients who had not received CTL developed aggressive disease and received CTL as treatment. Gene-marked CTL homed to tumor sites and selective accumulation of marker gene was detected in tumor tissues. Tumors regressed completely in two patients, but the third died of respiratory failure. Infused CTLs persisted for up to 3 years in vivo, they rapidly reconstituted EBV-specific immune responses to levels seen in normal individuals, and they reduced high viral titers by two to three logs. We are now using autologous EBV-specific CTL to treat patients with relapsed EBV-positive Hodgkin's disease and we are developing methods for the generation of antigen-specific lines. This approach could be applied to patients with HIV who develop EBV-LPD, using CTL derived early in the course of HIV infection.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
D. Adhikary, U. Behrends, R. Feederle, H.-J. Delecluse, and J. Mautner
Standardized and Highly Efficient Expansion of Epstein-Barr Virus-Specific CD4+ T Cells by Using Virus-Like Particles
J. Virol., April 15, 2008; 82(8): 3903 - 3911.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.